Bicycle Therapeutics–Cowen: investor conference, 201703 supply service Bicycle presents at Cowen & Co Annual Health Care Conference 2017

	Period	2017-03-07
	Region	Boston, MA
	Country	United States (USA)
	Partner, 1st	Bicycle Therapeutics Ltd.
	Group	Bicycle Therapeutics (Group)
	Partner, 2nd	Cowen & Company LLC
	Product	Cowen & Co. Annual Health Care Conference 2017 Boston
	Product 2	Bicycles® platform (bicyclic peptides)
	Person	Lee, Kevin (Bicycle Therapeutics 201509– CEO before Pfizer + GSK)
	Person 2	Sutton, Sarah (Argot Partners 202110 before WPP/Glover Park Group + Ten Bridge Communications)

Bicycle Therapeutics Ltd.. (3/2/17). "Press Release: Bicycle Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference". Cambridge, MA & Cambridge.

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (BicycleTM) product platform, announced today that Kevin Lee, Ph.D., Bicycle’s Chief Executive Officer, will present a company overview at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. The presentation will take place at 8:30 a.m. ET on Tuesday, March 7, 2017 in the MIT Room at the Boston Marriott Copley Place.

About Bicycle Therapeutics

Bicycle Therapeutics is developing a new class of medicines to treat oncology and other debilitating diseases based on its proprietary bicyclic peptide (BicycleTM) product platform. BicyclesTM exhibit an affinity and exquisite target specificity usually associated with antibodies, while a low molecular weight delivers rapid and deep tissue penetration enabling more efficient tumor targeting. Their peptidic nature provides a “tuneable” pharmacokinetic half-life and a renal route of clearance, avoiding the liver and gastrointestinal tract toxicities often seen with other drug modalities. Bicycle Therapeutics is rapidly advancing towards the clinic with its lead molecule, BT1718, and is collaborating in oncology and other areas to realize the full potential of the technology. Bicycle Therapeutics’ unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company, Sir Gregory Winter and Professor Christian Heinis. Bicycle Therapeutics is headquartered in Cambridge, U.K., with a U.S. subsidiary in Cambridge, Massachusetts. For more information, visit www.bicycletherapeutics.com.

Contacts:

Ten Bridge Communications (U.S.)
Sarah Sutton
Sarah@tenbridgecommunications.com
+1-857-242-1619

Consilium Strategic Communications (EU)
Mary-Jane Elliott / Chris Gardner / Ivar Milligan
Bicycle@consilium-comms.com
+44 20 3709 5700